
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3921056/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nurr1 Is Required for Maintenance of Maturing and Adult Midbrain Dopamine Neurons. Journal of Neuroscience, 2009, 29, 15923-15932.	1.7	320
2	Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice. Journal of Virology, 2005, 79, 214-224.	1.5	299
3	A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease. Molecular Therapy, 2010, 18, 1731-1735.	3.7	290
4	Neuroprotective Effects of Glial Cell Line-Derived Neurotrophic Factor Mediated by an Adeno-Associated Virus Vector in a Transgenic Animal Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2002, 22, 6920-6928.	1.7	244
5	Presynaptic Localization of Neprilysin Contributes to Efficient Clearance of Amyloid-Â Peptide in Mouse Brain. Journal of Neuroscience, 2004, 24, 991-998.	1.7	222
6	Gene Therapy for Aromatic <scp>l</scp> -Amino Acid Decarboxylase Deficiency. Science Translational Medicine, 2012, 4, 134ra61.	5.8	195
7	Triple Transduction with Adeno-Associated Virus Vectors Expressing Tyrosine Hydroxylase, Aromatic-L-Amino-Acid Decarboxylase, and GTP Cyclohydrolase I for Gene Therapy of Parkinson's Disease. Human Gene Therapy, 2000, 11, 1509-1519.	1.4	191
8	Behavioral Recovery in a Primate Model of Parkinson's Disease by Triple Transduction of Striatal Cells with Adeno-Associated Viral Vectors Expressing Dopamine-Synthesizing Enzymes. Human Gene Therapy, 2002, 13, 345-354.	1.4	182
9	Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Therapy, 2002, 9, 381-389.	2.3	164
10	lsolation and Characterization of Patient-derived, Toxic, High Mass Amyloid β-Protein (Aβ) Assembly from Alzheimer Disease Brains. Journal of Biological Chemistry, 2009, 284, 32895-32905.	1.6	162
11	Anterograde C1ql1 Signaling Is Required in Order to Determine and Maintain a Single-Winner Climbing Fiber in the Mouse Cerebellum. Neuron, 2015, 85, 316-329.	3.8	161
12	Nucleotide Sequencing and Generation of an Infectious Clone of Adeno-Associated Virus 3. Virology, 1996, 221, 208-217.	1.1	160
13	Gene therapy for mitochondrial disease by delivering restriction endonucleaseSmal into mitochondria. Journal of Biomedical Science, 2002, 9, 534-541.	2.6	151
14	Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein in mice. Neurobiology of Aging, 2008, 29, 574-585.	1.5	146
15	Synapse-specific representation of the identity of overlapping memory engrams. Science, 2018, 360, 1227-1231.	6.0	141
16	Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nature Medicine, 2012, 18, 1136-1141.	15.2	139
17	Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency. Brain, 2019, 142, 322-333.	3.7	116
18	CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. Scientific Reports, 2017, 7, 4159.	1.6	113

#	Article	IF	CITATIONS
19	Na, K-ATPase α3 is a death target of Alzheimer patient amyloid-β assembly. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4465-74.	3.3	112
20	Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's Disease. Human Gene Therapy Clinical Development, 2017, 28, 74-79.	3.2	109
21	Gene Therapy for Mitochondrial Disease by Delivering Restriction Endonuclease <i>Sma</i> I into Mitochondria. Journal of Biomedical Science, 2002, 9, 534-541.	2.6	106
22	Specific and efficient transduction of cochlear inner hair cells with recombinant adeno-associated virus type 3 vector. Molecular Therapy, 2005, 12, 725-733.	3.7	105
23	Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. Journal of General Virology, 2000, 81, 2077-2084.	1.3	105
24	Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. The Lancet Child and Adolescent Health, 2017, 1, 265-273.	2.7	96
25	Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Annals of Neurology, 2005, 57, 832-842.	2.8	86
26	Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Scientific Reports, 2013, 3, 1472.	1.6	83
27	Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport. Neuroscience Research, 2003, 45, 33-40.	1.0	66
28	<scp>HMGB</scp> 1 facilitates repair of mitochondrial <scp>DNA</scp> damage and extends the lifespan of mutant ataxinâ€1 knockâ€in mice. EMBO Molecular Medicine, 2015, 7, 78-101.	3.3	66
29	Retinoid X Receptor Gamma Control of Affective Behaviors Involves Dopaminergic Signaling in Mice. Neuron, 2010, 66, 908-920.	3.8	65
30	Regulatory Role of the GTP-Binding Protein, Go, in the Mechanism of Exocytosis in Adrenal Chromaffin Cells. Journal of Neurochemistry, 1992, 58, 2275-2284.	2.1	63
31	Gene therapy in Alzheimer's disease – potential for disease modification. Journal of Cellular and Molecular Medicine, 2010, 14, 741-757.	1.6	63
32	YAP-dependent necrosis occurs in early stages of Alzheimer's disease and regulates mouse model pathology. Nature Communications, 2020, 11, 507.	5.8	62
33	Sonographic detection of diffuse peripheral nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Clinical Ultrasound, 2000, 28, 488-491.	0.4	61
34	Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous <scp>AAV</scp> 9â€ <scp><i>ADAR</i></scp> <i>2</i> delivery to motor neurons. EMBO Molecular Medicine, 2013, 5, 1710-1719.	3.3	61
35	Tau binding protein CAPON induces tau aggregation and neurodegeneration. Nature Communications, 2019, 10, 2394.	5.8	59
36	Differential roles of the caudate nucleus and putamen in motor behavior of the cat as investigated by local injection of GABA antagonists. Neuroscience Research, 1991, 10, 34-51.	1.0	58

#	Article	IF	CITATIONS
37	Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Molecular Therapy, 2022, 30, 509-518.	3.7	58
38	Viral-Mediated Temporally Controlled Dopamine Production in a Rat Model of Parkinson Disease. Molecular Therapy, 2006, 13, 160-166.	3.7	54
39	Improved Safety of Hematopoietic Transplantation with Monkey Embryonic Stem Cells in the Allogeneic Setting. Stem Cells, 2006, 24, 1450-1457.	1.4	51
40	An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the <i>CACNA1A</i> second cistron. Science Translational Medicine, 2016, 8, 347ra94.	5.8	51
41	Systemic Delivery of Tyrosine-Mutant AAV Vectors Results in Robust Transduction of Neurons in Adult Mice. BioMed Research International, 2013, 2013, 1-8.	0.9	49
42	Multitracer assessment of dopamine function after transplantation of embryonic stem cellâ€derived neural stem cells in a primate model of Parkinson's disease. Synapse, 2009, 63, 541-548.	0.6	46
43	An A alpha Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation. Journal of Biological Chemistry, 1991, 266, 11575-11581.	1.6	45
44	Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Journal of Neuroscience Research, 2007, 85, 1752-1761.	1.3	42
45	Highly Efficient Gene Transfer into Primate Embryonic Stem Cells with a Simian Lentivirus Vector. Molecular Therapy, 2002, 6, 162-168.	3.7	41
46	The cardiac pacemaker-specific channel Hcn4 is a direct transcriptional target of MEF2. Cardiovascular Research, 2009, 83, 682-687.	1.8	41
47	The intellectual disability gene PQBP1 rescues Alzheimer's disease pathology. Molecular Psychiatry, 2018, 23, 2090-2110.	4.1	41
48	Protection Against Aminoglycoside-induced Ototoxicity by Regulated AAV Vector–mediated GDNF Gene Transfer Into the Cochlea. Molecular Therapy, 2008, 16, 474-480.	3.7	39
49	Hsp40 Gene Therapy Exerts Therapeutic Effects on Polyglutamine Disease Mice via a Non-Cell Autonomous Mechanism. PLoS ONE, 2012, 7, e51069.	1.1	38
50	Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator Journal of Clinical Investigation, 1992, 90, 67-76.	3.9	38
51	An A alpha Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation. Journal of Biological Chemistry, 1991, 266, 11575-81.	1.6	38
52	Regulation of the dopaminergic system in a murine model of aromatic l-amino acid decarboxylase deficiency. Neurobiology of Disease, 2013, 52, 177-190.	2.1	37
53	Ablation of NMDA Receptors Enhances the Excitability of Hippocampal CA3 Neurons. PLoS ONE, 2009, 4, e3993.	1.1	35
54	Role of the basal ganglia in manifestation of rhythmical jaw movement in rats. Brain Research, 1990, 535, 335-338.	1.1	32

4

#	Article	IF	CITATIONS
55	Current status of Kampo medicine curricula in all Japanese medical schools. BMC Complementary and Alternative Medicine, 2012, 12, 207.	3.7	32
56	TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. Journal of Clinical Investigation, 2019, 129, 3578-3593.	3.9	32
57	Adeno-associated virus vectors for gene transfer to the brain. Methods, 2002, 28, 237-247.	1.9	31
58	Preclinical substantia nigra dysfunction in rapid eye movement sleep behaviour disorder. Sleep Medicine, 2012, 13, 102-106.	0.8	31
59	In utero gene therapy rescues microcephaly caused by Pqbp1-hypofunction in neural stem progenitor cells. Molecular Psychiatry, 2015, 20, 459-471.	4.1	31
60	Artificial association of memory events by optogenetic stimulation of hippocampal CA3 cell ensembles. Molecular Brain, 2019, 12, 2.	1.3	30
61	Electrophysiological study of dyskinesia produced by microinjection of picrotoxin into the striatum of the rat. Neuroscience Research, 1990, 7, 369-380.	1.0	29
62	Overexpression of Shati/Nat8l, an N-acetyltransferase, in the nucleus accumbens attenuates the response to methamphetamine via activation of group II mGluRs in mice. International Journal of Neuropsychopharmacology, 2014, 17, 1283-1294.	1.0	29
63	Promoting Axon Regeneration in Adult CNS by Targeting Liver Kinase B1. Molecular Therapy, 2019, 27, 102-117.	3.7	29
64	A Neuron-Specific Gene Therapy Relieves Motor Deficits in Pompe Disease Mice. Molecular Neurobiology, 2018, 55, 5299-5309.	1.9	28
65	Benefits of Neuronal Preferential Systemic Gene Therapy for Neurotransmitter Deficiency. Molecular Therapy, 2015, 23, 1572-1581.	3.7	25
66	Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin. Biochemistry, 1993, 32, 2314-2320.	1.2	24
67	Compensatory Regulation of Dopamine after Ablation of the Tyrosine Hydroxylase Gene in the Nigrostriatal Projection. Journal of Biological Chemistry, 2011, 286, 43549-43558.	1.6	23
68	Inhibitory effects of Shati/Nat8l overexpression in the medial prefrontal cortex on methamphetamineâ€induced conditioned place preference in mice. Addiction Biology, 2020, 25, e12749.	1.4	23
69	An ultra-stable cytoplasmic antibody engineered for in vivo applications. Nature Communications, 2020, 11, 336.	5.8	22
70	A Novel Reporter Rat Strain That Conditionally Expresses the Bright Red Fluorescent Protein tdTomato. PLoS ONE, 2016, 11, e0155687.	1.1	21
71	Striatal N-Acetylaspartate Synthetase Shati/Nat8l Regulates Depression-Like Behaviors via mGluR3-Mediated Serotonergic Suppression in Mice. International Journal of Neuropsychopharmacology, 2017, 20, 1027-1035.	1.0	21
72	Enhancement of murine bone marrow macrophage differentiation by beta- endorphin. Blood, 1995, 86, 1316-1321.	0.6	20

#	Article	IF	CITATIONS
73	Choreiform movements in spinocerebellar ataxia type 1. Journal of the Neurological Sciences, 2001, 187, 103-106.	0.3	20
74	Efficient and stable Sendai virus-mediated gene transfer into primate embryonic stem cells with pluripotency preserved. Gene Therapy, 2005, 12, 203-210.	2.3	19
75	Variation in the Incidence of Teratomas after the Transplantation of Nonhuman Primate ES Cells into Immunodeficient Mice. Cell Transplantation, 2008, 17, 1095-1102.	1.2	19
76	Subregional 6-[18F]fluoro-ÊŸ-m-tyrosine Uptake in the Striatum in Parkinson's Disease. BMC Neurology, 2011, 11, 35.	0.8	19
77	A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies. Annals of Clinical Biochemistry, 2009, 46, 508-510.	0.8	18
78	Freezing of Gait in Parkinson's Disease Is Associated with Reduced 6-[¹⁸ F]Fluoro-L- <i>m</i> -tyrosine Uptake in the Locus Coeruleus. Parkinson's Disease, 2016, 2016, 1-5.	0.6	18
79	Overexpression of transmembrane protein 168 in the mouse nucleus accumbens induces anxiety and sensorimotor gating deficit. PLoS ONE, 2017, 12, e0189006.	1.1	18
80	Gene Therapy in a Mouse Model of Niemann–Pick Disease Type C1. Human Gene Therapy, 2021, 32, 589-598.	1.4	17
81	Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease. EMBO Molecular Medicine, 2021, 13, e14712.	3.3	17
82	Recombinant adeno-associated virus vector-transduced vascular endothelial cells express the thrombomodulin transgene under the regulation of enhanced plasminogen activator inhibitor-1 promoter. Gene Therapy, 2001, 8, 1690-1697.	2.3	16
83	Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors. Expert Opinion on Biological Therapy, 2005, 5, 663-671.	1.4	15
84	ERas is Expressed in Primate Embryonic Stem Cells but not Related to Tumorigenesis. Cell Transplantation, 2009, 18, 381-389.	1.2	15
85	RpA1 ameliorates symptoms of mutant ataxin-1 knock-in mice and enhances DNA damage repair. Human Molecular Genetics, 2016, 25, ddw272.	1.4	15
86	Gene therapy for <i>Glut1</i> â€deficient mouse using an adenoâ€associated virus vector with the human intrinsic GLUT1 promoter. Journal of Gene Medicine, 2018, 20, e3013.	1.4	15
87	Glucocorticoid receptor-mediated amygdalar metaplasticity underlies adaptive modulation of fear memory by stress. ELife, 2018, 7, .	2.8	15
88	Pcdhβ deficiency affects hippocampal CA1 ensemble activity and contextual fear discrimination. Molecular Brain, 2020, 13, 7.	1.3	15
89	Dopamine release via the vacuolar ATPase VO sector c-subunit, confirmed in N18 neuroblastoma cells, results in behavioral recovery in hemiparkinsonian mice. Neurochemistry International, 2012, 61, 907-912.	1.9	14
90	Knockdown of Dopamine D2 Receptors in the Nucleus Accumbens Core Suppresses Methamphetamine-Induced Behaviors and Signal Transduction in Mice. International Journal of Neuropsychopharmacology, 2015, 18, pyu038-pyu038.	1.0	14

#	Article	IF	CITATIONS
91	Neurotransmitter release: vacuolar ATPase VO sector c-subunits in possible gene or cell therapies for Parkinson's, Alzheimer's, and psychiatric diseases. Journal of Physiological Sciences, 2017, 67, 11-17.	0.9	14
92	Targeted expression of step-function opsins in transgenic rats for optogenetic studies. Scientific Reports, 2018, 8, 5435.	1.6	14
93	Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies. Scientific Reports, 2021, 11, 9322.	1.6	14
94	Striatal Shati/Nat8l–BDNF pathways determine the sensitivity to social defeat stress in mice through epigenetic regulation. Neuropsychopharmacology, 2021, 46, 1594-1605.	2.8	14
95	Hereditary antithrombin III deficiency with a superior sagittal sinus thrombosis: Evidence for a possible mutation starting in the mother of the propositus. Thrombosis Research, 1990, 57, 593-600.	0.8	13
96	Evaluation of 6- ¹¹ C-Methyl- <i>m</i> -Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with I²- ¹¹ C-l-DOPA and ¹⁸ F-FDOPA in Parkinson Disease Monkeys. Journal of Nuclear Medicine, 2016, 57, 303-308.	2.8	13
97	Alzheimer Aβ Assemblies Accumulate in Excitatory Neurons upon Proteasome Inhibition and Kill Nearby NAKα3 Neurons by Secretion. IScience, 2019, 13, 452-477.	1.9	13
98	Self-Contained Induction of Neurons from Human Embryonic Stem Cells. PLoS ONE, 2009, 4, e6318.	1.1	13
99	Current Status of Kampo Medicine in Community Health Care. General Medicine, 2012, 13, 37-45.	0.1	12
100	Gene therapy for a mouse model of glucose transporter-1 deficiency syndrome. Molecular Genetics and Metabolism Reports, 2017, 10, 67-74.	0.4	12
101	Dopaminergic restoration of prefrontal cortico-putaminal network in gene therapy for aromatic <scp>l</scp> -amino acid decarboxylase deficiency. Brain Communications, 2021, 3, fcab078.	1.5	12
102	The current status of gene therapy for Parkinson's disease. Annals of Neurosciences, 2010, 17, 92-5.	0.9	12
103	Induction of neuronal axon outgrowth by Shati/Nat8l by energy metabolism in mice cultured neurons. NeuroReport, 2015, 26, 740-746.	0.6	11
104	AADC Deficiency. Advances in Pharmacology, 2013, 68, 273-284.	1.2	10
105	Involvement of the accumbal osteopontin-interacting transmembrane protein 168 in methamphetamine-induced place preference and hyperlocomotion in mice. Scientific Reports, 2017, 7, 13084.	1.6	10
106	Gene therapy of Parkinson's disease using Adeno-Associated Virus (AAV) vectors. , 2000, , 181-191.		10
107	Recombinant adeno-associated viral vectors bring gene therapy for Parkinson's disease closer to reality. Journal of Neurology, 2002, 249, 1-1.	1.8	9
108	Efficient gene transfer of a simian immuno-deficiency viral vector into cardiomyocytes derived from primate embryonic stem cells. Journal of Gene Medicine, 2003, 5, 921-928.	1.4	9

#	Article	IF	CITATIONS
109	Vulnerability to depressive behavior induced by overexpression of striatal Shati/Nat8l via the serotonergic neuronal pathway in mice. Behavioural Brain Research, 2019, 376, 112227.	1.2	9
110	Maternal anticipation in Machado-Joseph disease (MJD): some maternal factors independent of the number of CAG repeat units may play a role in genetic anticipation in a Japanese MJD family. Journal of the Neurological Sciences, 1998, 155, 141-145.	0.3	8
111	Prediction of deficiency-excess pattern in Japanese Kampo medicine: Multi-centre data collection. Complementary Therapies in Medicine, 2019, 45, 228-233.	1.3	8
112	Deletion of Class II ADP-Ribosylation Factors in Mice Causes Tremor by the Nav1.6 Loss in Cerebellar Purkinje Cell Axon Initial Segments. Journal of Neuroscience, 2019, 39, 6339-6353.	1.7	8
113	Administration of tetrahydrobiopterin restored the decline of dopamine in the striatum induced by an acute action of MPTP. Neurochemistry International, 2019, 125, 16-24.	1.9	8
114	Discrimination of prediction models between cold-heat and deficiency-excess patterns. Complementary Therapies in Medicine, 2020, 49, 102353.	1.3	8
115	Schizophrenia-Like Behavioral Impairments in Mice with Suppressed Expression of Piccolo in the Medial Prefrontal Cortex. Journal of Personalized Medicine, 2021, 11, 607.	1.1	8
116	Intrastriatal gene delivery of GDNF persistently attenuates methamphetamine self-administration and relapse in mice. International Journal of Neuropsychopharmacology, 2013, 16, 1559-1567.	1.0	7
117	Mutational and functional analysis of Glucose transporter I deficiency syndrome. Molecular Genetics and Metabolism, 2015, 116, 157-162.	0.5	7
118	Regulatory system of mGluR group II in the nucleus accumbens for methamphetamineâ€induced dopamine increase by the medial prefrontal cortex. Neuropsychopharmacology Reports, 2019, 39, 209-216.	1.1	7
119	Intra-cisterna magna delivery of an AAV vector with the GLUT1 promoter in a pig recapitulates the physiological expression of SLC2A1. Gene Therapy, 2021, 28, 329-338.	2.3	7
120	Face-to-trait inferences in patients with Parkinson's disease. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 170-178.	0.8	6
121	Impairment of cognitive function induced by Shati/Nat8l overexpression in the prefrontal cortex of mice. Behavioural Brain Research, 2021, 397, 112938.	1.2	6
122	Transcription-positive cofactor 4 enhances rescue of adeno-associated virus genome from an infectious clone Journal of General Virology, 1998, 79, 2157-2161.	1.3	6
123	Probing links between action perception and action production in Parkinson's disease using Fitts' law. Neuropsychologia, 2018, 111, 201-208.	0.7	4
124	Gene Therapy with Virus Vectors for specific Disease of the Nervous System. International Review of Neurobiology, 2003, 55, 205-222.	0.9	3
125	GENE THERAPY FOR PARKINSON'S DISEASE: STRATEGIES FOR THE LOCAL PRODUCTION OF DOPAMINE. Gene Therapy and Regulation, 2010, 05, 57-65.	0.3	3
126	Electrical Abnormalities in Dopaminergic Neurons of the Substantia Nigra in Mice With an Aromatic L-Amino Acid Decarboxylase Deficiency. Frontiers in Cellular Neuroscience, 2019, 13, 9.	1.8	3

#	Article	IF	CITATIONS
127	Sonographic detection of diffuse peripheral nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Clinical Ultrasound, 2000, 28, 488-491.	0.4	3
128	Clobal brain delivery of neuroligin 2 gene ameliorates seizures in a mouse model of epilepsy. Journal of Gene Medicine, 2022, 24, e3402.	1.4	3
129	Retinoic acid receptor beta protects striatopallidal medium spiny neurons from mitochondrial dysfunction and neurodegeneration. Progress in Neurobiology, 2022, 212, 102246.	2.8	3
130	N-Acetyl Transferase, Shati/Nat8l, in the Dorsal Hippocampus Suppresses Aging-induced Impairment of Cognitive Function in Mice. Neurochemical Research, 2022, , 1.	1.6	3
131	Reduced Immunogenicity of Intraparenchymal Delivery of Adeno-Associated Virus Serotype 2 Vectors: Brief Overview. Current Gene Therapy, 2021, 21, .	0.9	2
132	Careful clinical observation is essential for diagnosis of Huntington's disease. Arquivos De Neuro-Psiquiatria, 2012, 70, 646-646.	0.3	2
133	Clinical Study of Scalloped Tongue Kampo Medicine, 1991, 42, 31-35.	0.1	2
134	Shati/Nat8l Overexpression Improves Cognitive Decline by Upregulating Neuronal Trophic Factor in Alzheimer's Disease Model Mice. Neurochemical Research, 2022, 47, 2805-2814.	1.6	2
135	Acupuncture and Knee Osteoarthritis. Annals of Internal Medicine, 2007, 146, 147.	2.0	1
136	Rhabdomyolysis caused by tocolytic therapy with oral ritodrine hydrochloride in a pregnant woman with placenta previa: Is this a rare case with a latent predisposing condition?. Journal of Obstetrics and Gynaecology Research, 2011, 37, 672-672.	0.6	1
137	Cell Therapy for Parkinson's Disease. , 2013, , 193-203.		1
138	Potential Changes within the Basal Ganglia during Putamen–Induced Dystonia and Caudate-Induced Locomotor Hyperactivity in the Freely Moving Cat. Advances in Behavioral Biology, 1994, , 327-336.	0.2	1
139	Gene Therapy for Parkinson Disease. The Japanese Journal of Rehabilitation Medicine, 2019, 56, 698-701.	0.0	1
140	Effective Treatment of Adult Parasomnias with Keishikaryukotsuboreito in Four Cases. Internal Medicine, 2022, , .	0.3	1
141	Advanced therapeutic strategy for hereditary neuromuscular diseases. Molecular Therapy, 2022, 30, 12-13.	3.7	1
142	Kampo Formula-Pattern Models: The Development of 13 New Clinically Useful Standard Abdominal Pattern Models in the Fukushin Simulator. Frontiers in Pharmacology, 2022, 13, 688074.	1.6	1
143	A phase 1 trial of gene delivery of aromatic L-amino acid decarboxylase for Parkinson disease. Neuroscience Research, 2009, 65, S24.	1.0	0
144	Amelioration of neurological phenotypes and inclusion body formation in polyglutamine disease mice upon AAV5-mediated expression of aggregate inhibitor molecules. Neuroscience Research, 2010, 68, e94.	1.0	0

#	Article	IF	CITATIONS
145	AADC gene therapy for Parkinson disease: Four years of follow-up. Neuroscience Research, 2011, 71, e101.	1.0	0
146	A pregnant woman with clinical and radiological findings compatible with posterior reversible encephalopathy syndrome in early pregnancy without discernable underlying disorders: Atypical type of this syndrome?. Journal of Obstetrics and Gynaecology Research, 2011, 37, 1137-1140.	0.6	0
147	201. Neuron-Specific Systemic Gene Therapy for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency. Molecular Therapy, 2015, 23, S80.	3.7	0
148	C-11. An Update on Gene Therapy for the Treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency. Molecular Therapy, 2015, 23, S103.	3.7	0
149	In vivo†gene therapy for Tay-Sachs and Sandhoff diseases by utilizing AAV9 vector encoding modified†HEXB. Molecular Genetics and Metabolism, 2019, 126, S78.	0.5	0
150	A novel bipolar syndrome animal model via reduction of Teneurin-4, the protein encoded by ODZ4, in the prefrontal cortex of mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2021, 94, 2-P1-40.	0.0	0
151	Effects of Senkyu-chacho-san on Motor Symptoms in Patients with Parkinson's Disease. Kampo Medicine, 2001, 51, 1087-1091.	0.1	0
152	Gene Therapy for Parkinson's Disease Using Aav Vectors. Advances in Behavioral Biology, 2002, , 459-462.	0.2	0
153	Gene therapy of Parkinson's disease: AAV vectors for delivery of therapeutic genes into mammalian brains. Ensho Saisei, 2003, 23, 218-222.	0.2	0
154	Gene Therapy for Parkinson Disease(<special issue="">Parkinson Disease). Japanese Journal of Neurosurgery, 2006, 15, 756-760.</special>	0.0	0
155	4.Gene Therapy for Parkinson's Disease(PS-9 Parkinson's Disease:To Overcome Side-effects of Dopa,The) Tj ETQq1 Neurosurgery, 2006, 15, 328.	1 0.7843 0.0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
156	AADC Deficiency. , 2014, , 3-4.		0
157	Fibrinogens Hamasaka and Tokyo III. Japanese Journal of Thrombosis and Hemostasis, 1991, 2, 286-292.	0.1	0
158	List of Serials in the Field of "Toyo-Igaku―(Oriental Medicine) indexed in JMEDICINE. Kampo Medicine, 1993, 43, 571-575.	0.1	0
159	Inhibitory effects of accumbal transmembrane protein 168 (TMEM168) on methamphetamine-induced place. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-85.	0.0	0
160	Cognitive dysfunction induced by the deletion of NAA synthase Shati/Nat8l in mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-14.	0.0	0
161	Inhibitory effect of knockdown Piccolo on methamphetamine-induced behavioral changes via dopamine/GABA release in the nucleus accumbens of mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-96.	0.0	0
162	Behavioral and neurochemical analyses in the Piccolo knockdown mice as a new animal model for schizophrenia. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-1-102.	0.0	0

#	Article	IF	CITATIONS
163	Vulnerability of social defeats in the overexpressed striatal SHATI/NAT8L in mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-1-71.	0.0	0
164	Inhibitory effects of Shati/Nat8l overexpression in the medial prefrontal cortex on the methamphetamine induced-CPP in mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-95.	0.0	0
165	Prediction Model for Deficiency-Excess Patterns, Including Medium Pattern. Kampo Medicine, 2020, 71, 315-325.	0.1	ο